| Literature DB >> 31404400 |
Christina K Rasmussen1, Estrid S Hansen2, Sham Al-Mashadi Dahl1, Erik Ernst3, Margit Dueholm1.
Abstract
OBJECTIVES: To assess the effect of transcervical endometrial resection on clinical symptoms related to histopathological findings of the junctional zone. STUDYEntities:
Keywords: Adenomyosis; Health-related quality of life; Heavy menstrual bleeding; Pelvic pain
Year: 2019 PMID: 31404400 PMCID: PMC6687372 DOI: 10.1016/j.eurox.2019.100029
Source DB: PubMed Journal: Eur J Obstet Gynecol Reprod Biol X ISSN: 2590-1613
Fig. 1Flowchart.
1 No adenomyosis of the inner myometrium and no reintervention surgery
2 Five with a histopathological diagnosis of adenomyosis of the inner myometrium and no reinterventions surgery. Two with serrated junctional zone had reintervention surgery (“no adenomyosis” verified by hysterectomy)
Patients with at least one follow-up questionnaire (6 or 18 months) were kept for the questionnaire analyses.
Reintervention surgery was recorded for all patients who completed baseline questionnaire (n = 126).
Fig. 2Left: Linear junctional zone, no or marginal myometrial invasion ≤ 3 mm with contact to the basal endometrium.
Middle: Serrated junctional zone, > 3 mm myometrial invasion with contact to the basal endometrium.
Right: Adenomyosis of the inner myometrium (intrinsic adenomyosis), ≥ 2 mm myometrial invasion without contact to the basal endometrium.
Baseline characteristics of patients scheduled for transcervical resection of the endometrium.
| All (n = 112) N | 95% CI 75% PI% | Adenomyosis of the inner myometrium (n = 24) N | 95% CI 75% PI % | Serrated junctional zone (n = 31) N | 95% CI 75% PI % | Linear junctional zone (n = 57) N | 95% CI 75% PI % | |
|---|---|---|---|---|---|---|---|---|
| Mean age | 45.2 | 44-46 | 45.5 | 44-47 | 45.1 | 43-47 | 45.1 | 43-47 |
| Median BMI1 | 26.1 | 23-29 | 27.1 | 24-28 | 26.5 | 23-29 | 24.7 | 22-29 |
| Mean number of pregnancies | 3 | 3-3 | 4 | 3-4 | 3 | 3-4 | 3 | 2-3 |
| Mean number of labors | 2 | 2-2 | 2 | 2-2 | 2 | 2-3 | 2 | 2-2 |
| Previous hysteroscopic surgery or myomectomy2 | 18 | 16% | 4 | 17% | 6 | 19% | 8 | 14% |
| Previous evacuation | 23 | 21% | 7 | 29% | 6 | 19% | 10 | 18% |
| Previous caesarean section | 16 | 14% | 3 | 13% | 10 | 52% | 3 | 5% |
| IUD or hormonal therapy before TCRE3 | 43 | 38% | 4 | 17% | 16 | 52% | 23 | 40% |
| IUD or hormonal therapy after TCRE4 | 34 | 30% | 6 | 25% | 10 | 32% | 18 | 32% |
| Ultrasound diagnosis of leiomyomas (all types) | 27 | 24% | 4 | 17% | 9 | 29% | 14 | 25% |
| Ultrasound diagnosis of leiomyomas | 16 | 24% | 2 | 8% | 5 | 16% | 9 | 16% |
| Ultrasound diagnosis of polyps | 10 | 9% | 3 | 13% | 0 | 0% | 7 | 12% |
| Mean thickness of endomyometrial biopsies | 5.3 | 5-6 | 5.4 | 5-6 | 5.4 | 5-6 | 5.2 | 5-5 |
CI: Confidence interval. PI: Percentile interval. BMI: Body Mass Index. IUD: Intrauterine device, TCRE: Transcervical resection of the endometrium.
There were no statistically significant differences (p-value <.05) between the groups (adenomyosis of the inner myometrium, serrated JZ and linear JZ) in baseline characteristics, except for mean number of pregnancies.
1One missing.
216 had resection of polyps, one had fibroid resection and one had myomectomy.
3Three months or more prior to operation.
4Five missing.
Surgical reintervention during follow-up according to histopathology and clinical symptoms.
| Baseline symptoms | Symptoms at 6 months follow-up | Use of analgesics after TCREα | Use of IUD after TCRE | Surgical reintervention | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| #1 | Adenomyosis of the inner myometrium | 37.5 | 56.0 | During (39) and between menstruation (30) | Hysterectomy | |||||
| #2 | Adenomyosis of the inner myometrium | 59.4 | 57.8 | No | Repeat TCRE* | |||||
| #3 | Serrated junctional zone | 53.1 | 40.5 | During (30) and between menstruation (15) | Hysterectomy | |||||
| #41 | Linear junctional zone | 56.3 | 50.0 | During (30) and between menstruation (88) | 21.9 | 93.7 | Between menstruation (87) | Yes | Yes | Hysterectomy |
| #5 | Adenomyosis of the inner myometrium | 62.5 | 41.4 | During (87) and between menstruation (62) | 56.3 | 46.6 | During (90) and between menstruation (70) | Yes | Yes | Repeat TCRE* |
| #6 | Adenomyosis of the inner myometrium | 53.1 | 75.9 | No | 18.8 | 89.7 | During menstruation (22) | Yes | No | Repeat TCRE* |
| #7 | Adenomyosis of the inner myometrium | 78.1 | 42.2 | No | 43.8 | 81.0 | No | No | No | Hysterectomy |
| #8 | Adenomyosis of the inner myometrium | 62.5 | 42.2 | During (71) and between menstruation (65) | 15.6 | 90.5 | Between menstruation (14) | Yes | No | Hysterectomy |
| #92 | Linear junctional zone | 56.3 | 75.0 | During (77) and between menstruation (71) | 53.1 | 82.8 | During (56) and between menstruation (58) | Yes | Yes | Hysterectomy |
| #10 | Serrated junctional zone | 12.5 | 80.2 | No | 9.4 | 69.8 | Between menstruation (23) | No | Yes | Hysterectomy |
| #11 | Serrated junctional zone | 50.0 | 44.8 | During menstruation (78) | Hysterectomy | |||||
| #12 | Serrated junctional zone | 18.8 | 81.9 | During (85) and between menstruation (80) | Hysterectomy | |||||
| #13 | Adenomyosis of the inner myometrium | 71.9 | 63.8 | During (65) and between menstruation (23) | 6.3 | 90.5 | No | No | No | Hysterectomy |
| #14 | Adenomyosis of the inner myometrium | 62.5 | 49.1 | During menstruation (72) | 53.1 | 61.2 | During menstruation (54) | Yes | No | Hysterectomy |
| #15 | Linear junctional zone | 34.4 | 30.2 | No | 65.6 | 7.8 | During (63) and between menstruation (60) | Yes | No | Hysterectomy |
TCRE: Transcervical resection of the endometrium. SSS: Symptom severity. HR-QoL: Health-related quality of life. VAS: Visual analogue scale. IUD: Intrauterine device.
#1-3 had surgical reintervention < 6 months after TCRE, #4-12 had surgical reintervention 6–18 months after TCRE and #13-15 had surgical reintervention > 18 months after TCRE (before January 2018). Follow-up questionnaire missing in #11 and #12.
* All three patients had subsequently hysterectomy due to persisting symptoms.
Presence or absence of adenomyosis of the inner myometrium was verified in all hysterectomy specimens except for patient #2. This patient had one foci of adenomyosis of the inner myometrium, and it is likely that this foci may have been removed by repeat TCRE prior to hysterectomy.
α Reported use at 6 months follow-up, including paracetamol, aspirin, non-steroidal anti-inflammatory drugs.
1 Concomitant uterine polyps.
2 Concomitant leiomyomas.
Symptom severity and health-related quality of life at baseline and follow-up after transcervical resection of the endometrium.
| Baseline (n = 112) | 6 months follow-up (n = 105)1 | 6 months improvement | 18 months follow-up (n = 96)2 | 18 months improvement | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Median | 75% PI | N | Median | 75% PI | Mean | 95% CI | Difference | N | Median | 75% PI | Mean | 95% CI | Difference | |
| Adenomyosis of the inner myometrium | 24 | 59.4 | 48-66 | 22 | 18.8 | 9-44 | 34.4 | 25-44 | p-value >.05* | 15 | 18.8 | 6-19 | 39.8 | 30-50 | p-value > .05 |
| Serrated junctional zone | 31 | 50.0 | 34-63 | 29 | 9.4 | 6-25 | 33.4 | 25-41 | 28 | 10.9 | 3-19 | 35.0 | 28-42 | ||
| Linear junctional zone | 57 | 56.3 | 44-72 | 54 | 7.8 | 0-25 | 41.6 | 35-48 | 53 | 9.4 | 3-22 | 42.3 | 36-48 | ||
| Adenomyosis of the inner myometrium | 24 | 56.5 | 46-63 | 22 | 85.8 | 69-91 | 22.9 | 17-29 | p-value ≤ .05 | 15 | 90.5 | 76-95 | 28.6 | 21-37 | p-value > .05 |
| Serrated junctional zone | 31 | 56.0 | 42-66 | 29 | 93.1 | 83-97 | 31.0 | 22-40 | 28 | 93.1 | 80-97 | 30.7 | 22-39 | ||
| Linear junctional zone | 57 | 49.1 | 40-63 | 54 | 94.0 | 84-98 | 36.3 | 31-41 | 53 | 92.2 | 86-98 | 35.4 | 29-42 | ||
SSS: Symptom severity score. HR-QoL: Health-Related Quality of Life. PI: Percentile interval, CI: Confidence interval.
No subscale score was considered missing.
1 6 months follow-up questionnaire missing in four patients (these patients did not have surgical reintervention), three patients excluded due to reintervention surgery within the follow-up period.
2 18 months follow-up questionnaire missing in six patients (one of the patients had reintervention), ten patients exclude due to reintervention surgery within the follow-up period.
No statistically significant difference in baseline SSS and HR-QoL between the groups (p-value > 0.05).
*Statistically significant difference in 6 months follow-up SSS and HR-QoL between patients with either serrated junctional zone or adenomyosis of the inner myometrium and linear junctional zone (p-value ≤ .05).
Fig. 3Health-related quality of life on a scale from 0 to 100 at baseline, 6 and 18 months follow-up.
Pelvic pain at baseline and follow-up after transcervical resection of the endometrium.
| Baseline (n = 112) | 6 months follow-up (n = 105)1 | 18 months follow-up (n = 96)2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | With pain N (%) | VAS* Median % | 75% PI | N | With pain N (%) | VAS* Median % | 75% PI | N | With pain N (%) | VAS* Median % | 75% PI | |
| Adenomyosis of the inner myometrium | 24 | 18 (75) | 67 | 51-73 | 22 | 7 (32) | 52 | 22-67 | 15 | 2 (13) | 26 | 17-35 |
| Serrated junctional zone | 31 | 21 (68) | 60 | 38-68 | 29 | 5 (17) | 35 | 32-57 | 28 | 7 (25) | 59 | 50-70 |
| Linear junctional zone | 57 | 45 (79) | 57 | 36-70 | 54 | 15 (28) | 56 | 11-63 | 53 | 11 (21) | 31 | 20-39 |
| Adenomyosis of the inner myometrium | 24 | 11 (46) | 30 | 17-62 | 22 | 5 (23) | 42 | 19-56 | 15 | 0 | 0 | |
| Serrated junctional zone | 31 | 14 (45) | 40 | 24-50 | 29 | 8 (28) | 25 | 21-39 | 28 | 3 (11) | 35 | 15-53 |
| Linear junctional zone | 57 | 29 (51) | 39 | 25-63 | 54 | 15 (28) | 37 | 5-60 | 53 | 11 (21) | 40 | 12-47 |
VAS: Visual Analogue Scale. PI: Percentile interval, CI: Confidence interval.
*Average pain.
1 6 months follow-up questionnaire missing in four patients (these patients did not have reintervention surgery), three patients excluded due to reintervention surgery within the follow-up period.
2 18 months follow-up questionnaire missing in six patients (one of the patients had reintervention), ten patients exclude due to reintervention surgery within the follow-up period.
There was no statistically significant difference in baseline or follow-up pelvic pain and VAS intensity between groups (p-value > 0.05).
Before surgery more than 50% in each of the three groups used analgesic drugs; this was reduced to less than 20% at 18 months follow-up.